EUVIMEDSkopri EUVIMED
Open access

Intraventricular immunovirotherapy; a translational step forward

Joshua D Bernstock, Sarah Blitz, Kyung-Don Kang, Gregory K Friedman

Oncotarget · 2023

DOI: 10.18632/oncotarget.28343 ↗

At a glance

Journal article in Oncotarget, 2023. Written by Joshua D Bernstock and 3 co-authors. Institution: Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Major MEDLINE topics: Oncolytic Viruses, Oncolytic Virotherapy, Glioma, Cerebellar Neoplasms. Cited 7 times so far (Crossref). The full text is freely available in PubMed Central.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Oncolytic virotherapy with intratumoral engineered type-1 herpes simplex virus (HSV) has been proven safe with promising efficacy in recent clinical trials for treatment of both pediatric and adult high-grade glioma. However, this approach excludes patients with tumors in surgically inaccessible and/or eloquent brain regions. Current delivery methods are also unable to access/treat those patients with metastatic disease in the spinal cord and/or leptomeningeal disease. A recent preclinical study has paved the way for clinical translation of intraventricular administration of oHSV by identifying and mitigating the toxicity associated with this route for therapeutic benefit in murine models of disseminated medulloblastoma. This work may ultimately allow for targeting of intractable disease and provides a feasible option for the repetitive dosing of clinically relevant immunovirotherapy, G207.

Subjects

MeSH terms (MEDLINE)

Oncolytic VirusesOncolytic VirotherapyGliomaCerebellar NeoplasmsAdultHumansChildMiceAnimalsSimplexvirus

Author keywords

G207herpes simplex virus (HSV)intraventricular therapyleptomeningeal diseaseoncolytic virotherapy

Authors and institutions

  • Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Department of Pediatrics, Division of Pediatric Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.

Cite

APA

Bernstock, J. D., Blitz, S., Kang, K. D., & Friedman, G. K. (2023). Intraventricular immunovirotherapy; a translational step forward. Oncotarget. https://doi.org/10.18632/oncotarget.28343

Vancouver

Bernstock JD, Blitz S, Kang KD, Friedman GK. Intraventricular immunovirotherapy; a translational step forward. Oncotarget. 2023. doi:10.18632/oncotarget.28343

BibTeX
@article{Bernstock2023,
  author = {Bernstock, Joshua D and Blitz, Sarah and Kang, Kyung-Don and Friedman, Gregory K},
  title = {Intraventricular immunovirotherapy; a translational step forward},
  journal = {Oncotarget},
  year = {2023},
  doi = {10.18632/oncotarget.28343}
}
Start for free →